

Applicant(s) : Guangwen WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 7

Amendments to the Claims:

Please cancel claims 29-37 without prejudice to applicants' rights to pursue the subject matters in a further application.

Please add the following new claims:

38. (New) A recombinant super-compound interferon with changed spatial configuration and higher efficacy than IFN-con without change to the primary sequence.

39. (New) A recombinant super-compound interferon of claim 38 with SEQ ID NO:2.

40. (New) The interferon of claim 38, wherein the interferon is α , β , or ω .

41. (New) A super-compound interferon of claim 38, produced by a high efficiency expression system which uses a special promoter.

42. (New) The super-compound interferon of claim 41, wherein the promoter is P_{BAD}.

43. (New) The super-compound interferon of claim 42, wherein its gene is artificially synthesized cDNA with adjustment of its sequence from the wild-type according to codon preference of E. coli.

44. (New) The super-compound interferon of claim 38, which possesses anti-viral or anti-tumor activity.

Applicant(s) : Guangwen WEI, et al.
U.S. Serial No.: 10/650,365
Filed : August 28, 2003
Page : 8

45. (New) The super-compound interferon of claim 44, which directly inhibits the DNA duplication and secretion of HBsAg and HBeAg of Hepatitis B Virus.

46. (New) A composition comprising the recombinant super-compound interferon of claim 38.

47. (New) A pharmaceutical composition comprising the recombinant super-compound interferon of claim 38 and a pharmaceutically acceptable carrier.